Souhaitez-vous accéder aux communiqués récents ?

ECM Therapeutics receives FDA 510(k) clearance for ECMT-100 WMD, validating its extracellular matrix hydrogel platform.

New name reflects the company’s growth from a regenerative medicine innovator into a broader therapeutics company, with its clinical-stage cell therapy programs remaining at the core SAN DIEGO, June ...

Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body...

Pluristyx issued Japan patent allowance for next-gen synthetic mRNA, accelerating non-viral, footprint-free iPSC generation for regenerative medicine

Austin, United States, June 09, 2026 (GLOBE NEWSWIRE) -- “According to SNS Insider, the Tissue Engineered Skin Substitutes Market was valued at USD 1.59 billion in 2025 and is projected to reach USD...

Merakris announces FDA Fast Track designation for MTX-001, its lead biologic candidate for the treatment of venous leg ulcers.

TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company...

Repairon announces NEJM publication concluding that heart muscle restoration is achievable in patients, resulting in improved health and quality of life.

Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Biologics Contract Manufacturing Market (7th Edition) by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale...

TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company...